Amy Hawkins
Acute Care · Cincinnati, OHNPI 1881027555
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,762 of the $6,733 with a category attached, or 85.6%. 30 manufacturers reported payments, led by Abbott at 49.1% of the total. Reporting peaked in 2023 at $2,233 and has fallen 81.1% since, to $421 in 2025. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Novartis$763
- Boehringer Ingelheim$433
- Johnson & Johnson$346
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$262
- AstraZeneca$240
- plus $1K from 24 others
What the payments were for
- Travel & lodging$91114%
- Food & beverage$5,76286%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 98 | $3,308 |
| Novartis | 57 | $763 |
| Boehringer Ingelheim | 20 | $433 |
| Johnson & Johnson | 32 | $346 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $262 |
| AstraZeneca | 12 | $240 |
| Pfizer | 10 | $208 |
| Cvrx, Inc. | 3 | $165 |
| Boston Scientific | 5 | $121 |
| Scpharmaceuticals Inc. | 1 | $121 |
| Merck | 6 | $92 |
| AbbVie | 1 | $76 |
| Bayer | 3 | $63 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Amgen | 4 | $61 |
| Philips North America LLC | 3 | $51 |
| Novo Nordisk | 3 | $49 |
| Vifor Pharma, Inc. | 2 | $44 |
| Abiomed | 1 | $30 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Vital Connect, Inc | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 2 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Atricure, Inc. | 1 | $22 |
| Heartflow, Inc. | 1 | $20 |
| Medline Industries LP | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Recor Medical Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,394
- CardioMEMS HF System$291
- Barostim Neo System$149
- FUROSCIX$121
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$110
- VYNDAQEL$100
How this compares
$6,733 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 86 | $64,441 |
| JardianceEmpagliflozin | 58 | $46,266 |
| EliquisApixaban | 43 | $44,602 |
| FarxigaDapagliflozin Propanediol | 15 | $18,219 |
| BrilintaTicagrelor | 24 | $11,899 |
| Torsemide | 92 | $2,208 |
| Ranolazine ErRanolazine | 11 | $937 |
| Amiodarone Hcl | 18 | $611 |
| Furosemide | 141 | $501 |
| Metoprolol Succinate | 57 | $464 |
| Midodrine Hcl | 12 | $417 |
| Atorvastatin Calcium | 54 | $391 |
| ClopidogrelClopidogrel Bisulfate | 62 | $311 |
| Klor-Con M20Potassium Chloride | 15 | $274 |
| Hydralazine Hcl | 23 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $763 | $64,44186 claims |
| Boehringer IngelheimJardiance | $433 | $46,26658 claims |
| PfizerEliquis | $208 | $44,60243 claims |
| AstraZenecaFarxiga, Brilinta | $240 | $30,11839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Cincinnati
- Julie LurieCincinnati$13K
- Laura LangenhopCincinnati$8K
- Jennifer ClarkCincinnati$7K
- Rebecca BlantonCincinnati$6K
- Carrie MyersCincinnati$6K
- Kathleen RoederCincinnati$6K
- Nicole BrownCincinnati$5K
- Donna AbdelnourCincinnati$5K
- Bonnie AlbertCincinnati$4K
- Jessica HendrixCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.